About the Company
We do not have any company description for CEL SCI CORP at the moment.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CEL SCI CORP
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
VIENNA, Va., August 15, 2024--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.
CEL-SCI Corporation Completes Commercial-Scale Buildout of ... - Nasdaq
CEL-SCI Corporation today announced it has completed the expansion of its existing dedicated Multikine* cGMP manufacturing facility. Following an $11 million investment to increase production, CEL ...
CEL-SCI Corporation: CEL-SCI to Sign Partnership Agreement With Leading ...
CEL-SCI CORPORATION WKN: A418TVISIN: US1508377066Ticker-Symbol: LSR NASDAQ 13.08.25 | 21:56 8,295 0,00 % 0,000 Branche Biotechnologie Aktienmarkt Sonstige 1-Jahres-Chart 5-Tage-Chart Nachrichten ...
CEL-SCI Corporation Receives Approval from First Taiwanese ...
For more information, please visit www.cel-sci.com. CONTACT: CEL-SCI Corporation Gavin de Windt, 703-506-9460 KEYWORDS: United States Asia Pacific North America Virginia Taiwan ...
CEL-SCI Corporation Announces the Closing of Its $4 Million Registered ...
VIENNA, Va.-- (BUSINESS WIRE)-- CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its ...
Technical And Fundamental Breakout In Play For CEL-SCI Corporation
CEL-SCI expects to conclude the Multikine Phase III clinical trials by May 2015. Given the time lag expected for data read out from this humongous trial, the immunotherapy may be launched in the ...
Why CEL-SCI Corporation (CVM) Shares Are Diving
CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares. Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 ...
CEL-SCI Announces Bought Deal Offering - Nasdaq
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has ...
A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
Cel-Sci Corporation (NYSEMKT: CVM) is on the verge of several significant milestones and inflection points during the first several months of 2016.
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
Following the end of the third quarter of fiscal 2024, on July 29, 2024, CEL-SCI closed on an equity fundraise of $10.85 million. About CEL-SCI Corporation ...
Similar Companies
Loading the latest forecasts...